NCT03381768View on ClinicalTrials.gov

Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 12, 2017

Primary Completion Date

February 12, 2020

Study Completion Date

February 12, 2020

Conditions
Follicular Lymphoma
Interventions
BIOLOGICAL

PD-L2 peptide

100 ug PD-L2 peptide dissolved in DMSO and water mixed with 500ul montanide.

BIOLOGICAL

PD-L2 and PD-L1 peptide

100 ug PD-L2 peptide and 100ug PD-L1 peptide dissolved in DMSO and water mixed with 500ul montanide.

Trial Locations (1)

2730

Herlev Hospital, Herlev

All Listed Sponsors
lead

Lars Møller Pedersen

OTHER

NCT03381768 - Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma | Biotech Hunter | Biotech Hunter